Search
Prinomastat
go.drugbank.com/drugs/DB05100InvestigationalAs a lipophilic agent, prinomastat crosses the blood-brain barrier.
VB2-011
go.drugbank.com/drugs/DB05411ExperimentalVB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.
DP-b99
go.drugbank.com/drugs/DB05820InvestigationalDP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment
Nadide
go.drugbank.com/drugs/DB14128InvestigationalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
Oxytocin
go.drugbank.com/drugs/DB00107ApprovedInvestigationalVet approvedSir Henry H. Dale first identified oxytocin and its uterine contractile properties in 1906. Like all other neurohypophysial hormones, oxytocin is composed of nine amino acids with a disulfide bridge between the Cys 1 and 6 residues. In t...
Carboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Allopurinol
go.drugbank.com/drugs/DB00437ApprovedInvestigationalGout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several ...
Zolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalZolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia.
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalTividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099